Published: 13 January 2015

Surrey announces new research partnership to explore type 2 diabetes

Five-year collaboration with Eli Lilly and Company will explore health outcomes for people with the disease.

The University of Surrey will work with global healthcare leader Eli Lilly and Company to study the effects of treatment on people with type 2 diabetes, which affects about 95 per cent of those with the disease.

Using routine data gathered from patients undergoing diabetes treatments, the partnership will focus on answering commonly asked clinical questions about the continuum of diabetes care, such as the role and timing of injectable therapy, factors impacting adherence to prescribed medicines and the pattern and rationale of therapy following diagnosis.

The collaboration will initially focus on three key areas: adherence to therapy, triggers for the initiation of injectable therapy, and understanding the perspectives of both the patient and healthcare professional.

“Diabetes is a complex condition to manage, requiring each patient to be treated and supported in a variety of ways,” said Professor Simon de Lusignan, Head of the Department of Health Care Management and Policy. “Our research uses routine data to help busy clinicians incorporate innovation into routine practice, focusing on those diseases that pose the highest risk. By understanding how effectively individual care plans work, we can learn how to improve and enhance diabetes care more broadly.

“Our aim is to ensure that those suffering with the disease receive treatments that allow them to continue living their lives in the fullest sense, with effective support in place.”

Diabetes remains one of society’s most prevalent diseases. More than 387 million people worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common, accounting for an estimated 90 to 95 per cent of all diabetes cases. Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.

Dara Schuster MD, Medical Fellow at Eli Lilly and Company, commented: “Diabetes is a long and complex journey for patients and their caregivers, as well as a personal one. It’s important for clinicians to understand each step of that journey so patients can reach optimal outcomes. We are honoured to collaborate with an esteemed institution like the University of Surrey on this important project.”

Discover more about Surrey’s programmes in Health Care Management and Health Economics, or explore our research in Health Care Management and Policy.

Share what you've read?